News

The partnership will identify potent, selective and orally bioavailable small molecules that inhibit PTP1B activity in-vivo following stimulation by insulin and leptin to overcome resistance encountered in diabetes and obesity. Under the multi-year deal, CSHL and...

Japanese drug maker Takeda Pharmaceutical Company, through its wholly owned subsidiary Millennium Pharmaceuticals, has signed an agreement with US-based ImmunoGen to develop and commercialise anti-cancer therapeutics up to two undisclosed targets. As part of the deal,...

US-based Eli Lilly and Company has partnered with Chinese drug development firm Innovent Biologics to develop and commercialise three cancer treatments over the next decade. The deal will expand the presence of both firms in the...

Swedish firm Dilaforette has received orphan drug designation from the US Food and Drug Administration (FDA) for its sevuparin (DF02) to treat patients with sickle-cell disease (SCD). With an aim to start recruitment of patients during...

Germany-based Evotec has signed an agreement with French drugmaker Sanofi for a major multi-component strategic partnership over the next five years. As part of the deal, Sanofi will provide around €250m to Evotec, including more than...

US-based Eli Lilly and Company has signed an exclusive licence and collaboration agreement with Hanmi Pharmaceutical to develop and commercialise an immunological therapy. Under the deal, both firms will develop Hanmi's oral Bruton's tyrosine kinase (BTK)...

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in children aged between two and five years. The approval allows the drug to...